Tue, Jul 22, 2014, 7:46 PM EDT - U.S. Markets closed

Recent

% | $
Click the to save as a favorite.

Insmed Incorporated Message Board

  • blank2thisone blank2thisone May 20, 2013 3:15 PM Flag

    Blockbuster - ((30k + 35k)/2+50k))*$30k=$1.5billion, ....

    ...conservatively.. Only cf and ntm (us)

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Solid and extensive patent estate expected through 2029
       3 issued patents in the U.S., total of 20 issued/allowed
      patents and 61 pending applications worldwide
       Claims cover methods of use, composition of matter and
      delivery of drug
       Nebulizer device exclusivity for a minimum of 15 years
       Orphan drug status granted for CF and NTM

      Sentiment: Strong Buy

    • We have two near-term commercial opportunities in orphan lung diseases.
      Europe: ARIKACE Phase 3 trial to treat CF patients with Pseudomonas lung infections enrollment completed
      US: ARIKACE Phase 2 trial to treat NTM enrollment well underway. Potential accelerated path to approval
      We have near-term value-driving milestones.
      Phase 3 CF-related Pseudomonas lung infection data expected in mid-2013
      Phase 2b NTM lung infection data expected by year end 2013
      We have a solid and broad IP portfolio.
      More than a decade of investment in research and development
      Potential coverage into 2029

      Sentiment: Strong Buy

      • 1 Reply to blank2thisone
      • Pseudomonas lung infections in cystic fibrosis patients
         CF is a serious and fatal disease with no existing cure and a
        life expectancy of just 37 years1
         CF affects ~30,000 patients in the US2 and ~35,000 patients
        in Europe3
         Urgent need for better, safer, more effective treatments
         Current treatments require dosing 2x-3x per day for up to 40
        minutes of total treatment time; studies show decline in lung function below baseline after off-treatment periods
        Nontuberculous mycobacteria (NTM) lung infections
         Debilitating disease with no FDA approved therapy
         Off-label treatments have significant toxicities and limitations
         ~50,000 cases in US4, growing 8% per year5

        Sentiment: Strong Buy

 
INSM
17.70-0.04(-0.23%)Jul 22 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.